Search details
1.
Relationship between insurance status and interhospital transfers among cancer patients in the United States.
BMC Cancer
; 22(1): 121, 2022 Jan 29.
Article
in English
| MEDLINE | ID: mdl-35093015
2.
Early imaging marker of progressing glioblastoma: a window of opportunity.
J Neurooncol
; 148(3): 629-640, 2020 Jul.
Article
in English
| MEDLINE | ID: mdl-32602020
3.
A risk model for prediction of 30-day readmission rates after surgical treatment for colon cancer.
Int J Colorectal Dis
; 35(8): 1529-1535, 2020 Aug.
Article
in English
| MEDLINE | ID: mdl-32377912
4.
Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.
J Neurooncol
; 145(1): 97-105, 2019 Oct.
Article
in English
| MEDLINE | ID: mdl-31456142
5.
Comprehensive Genomic Profiling of Esthesioneuroblastoma Reveals Additional Treatment Options.
Oncologist
; 22(7): 834-842, 2017 07.
Article
in English
| MEDLINE | ID: mdl-28495808
6.
A phase II trial of enzastaurin (LY317615) in combination with bevacizumab in adults with recurrent malignant gliomas.
J Neurooncol
; 127(1): 127-35, 2016 Mar.
Article
in English
| MEDLINE | ID: mdl-26643807
7.
A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas.
J Neurooncol
; 125(1): 191-5, 2015 Oct.
Article
in English
| MEDLINE | ID: mdl-26285768
8.
Biphasic IDH1 phenotype in a diffusely infiltrating glioma: implications for pathogenesis, treatment and prognosis.
Clin Neuropathol
; 34(5): 282-7, 2015.
Article
in English
| MEDLINE | ID: mdl-25907263
9.
Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations.
Cancer
; 125(17): 2910-2914, 2019 09 01.
Article
in English
| MEDLINE | ID: mdl-31314136
10.
Bevacizumab-related toxicities in the National Cancer Institute malignant glioma trial cohort.
J Neurooncol
; 120(2): 431-40, 2014 Nov.
Article
in English
| MEDLINE | ID: mdl-25098701
11.
An Update on H3K27M-altered Diffuse Midline Glioma: Diagnostic and Therapeutic Challenges in Clinical Practice.
Pract Radiat Oncol
; 2024 May 03.
Article
in English
| MEDLINE | ID: mdl-38704025
12.
Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.
Neuro Oncol
; 26(Supplement_2): S165-S172, 2024 May 03.
Article
in English
| MEDLINE | ID: mdl-38386699
13.
An overview of the therapeutic strategies for neoplastic meningitis due to breast cancer: when and why?
Expert Rev Neurother
; 24(1): 77-103, 2024.
Article
in English
| MEDLINE | ID: mdl-38145503
14.
Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma.
Neuro Oncol
; 26(Supplement_2): S155-S164, 2024 May 03.
Article
in English
| MEDLINE | ID: mdl-38400780
15.
ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma.
J Clin Oncol
; 42(13): 1542-1552, 2024 May 01.
Article
in English
| MEDLINE | ID: mdl-38335473
16.
cMYC expression in infiltrating gliomas: associations with IDH1 mutations, clinicopathologic features and outcome.
J Neurooncol
; 115(2): 249-59, 2013 Nov.
Article
in English
| MEDLINE | ID: mdl-23934175
17.
Key Clinical Principles in the Management of Glioblastoma.
JCO Oncol Pract
; 19(4): 180-189, 2023 04.
Article
in English
| MEDLINE | ID: mdl-36638331
18.
DNA Methylation and Histone Modification in Low-Grade Gliomas: Current Understanding and Potential Clinical Targets.
Cancers (Basel)
; 15(4)2023 Feb 20.
Article
in English
| MEDLINE | ID: mdl-36831683
19.
Surgically targeted radiation therapy (STaRT) for recurrent brain metastases: Initial clinical experience.
Brachytherapy
; 22(6): 872-881, 2023.
Article
in English
| MEDLINE | ID: mdl-37722990
20.
Treatment of glioblastoma using MRIdian® A3i BrainTx™: Imaging and treatment workflow demonstration.
Med Dosim
; 48(3): 127-133, 2023.
Article
in English
| MEDLINE | ID: mdl-36966049